drugset
drugset / Trial / NCT01289730

Etanercept (Enbrel) in Undifferentiated Spondyloarthritis

NCT01289730 ↗

Phase 2 Unknown 8 enrolled Charite University, Berlin, Germany Rheumazentrum Ruhrgebiet · collab
NaSingle-groupOpen-labelTreatment

Summary

The study has the aim to investigate the efficacy and safety of etanercept in patients with active undifferentiated spondyloarthritis (uSpA) over the period of 520 weeks.

Timeline

Start
2002-02
Primary completion
2003-09
Completion
2012-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic 25 mg Subcutaneous

Indications

spondyloarthropathy